Atlas Trials

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Clinical trial NCT05847569 · RECRUITING

Trial details

NCT number
NCT05847569
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Start date
2024-01-04
Primary completion
2029-06-29
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.